TEVA's ANDA219413 Submission Signals Potential Market Disruption
Not specified • Regulatory Approval • Jun 18, 2026
Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The submission of ANDA219413 by TEVA Pharmaceuticals is significant as it represents a potential entry of a generic product into the market. This could alter pricing dynamics and competitive positioning within the relevant therapeutic area, which is currently unspecified. Regulatory context from FDA (FDA TA — ANDA219413) supports the near-term read. Assessment grounded in 19 ranked evidence items (6 high-relevance).
Strategic Assessment
Portfolio and strategy teams should assess the potential market entry of this generic product and its implications for pricing and competition. The strongest clinical anchor is Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children (ClinicalTrials.gov), mechanism alignment (io ). In Not specified, 5 regulatory and 2 competitive items passed relevance filtering for TEVA PHARMACEUTICALS, INC.
Competitive Pressure
The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This submission may impact the competitive landscape for generic alternatives in the relevant therapeutic area, depending on the product's specifics.
Regulatory Outlook
Regulatory risk is concentrated around FDA TA — ANDA219413 (FDA). Entity match (teva pharmaceuticals inc); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The standard review priority indicates a typical timeline for FDA evaluation, which could affect the timing of market entry for this generic product.
Key Risks
- Elevated medium regulatory exposure for TEVA PHARMACEUTICALS, INC could delay market entry or constrain labeling if agency review intensifies.
Key Opportunities
- The introduction of a generic alternative could lead to price reductions and increased competition, impacting market share for existing branded products.
- Upside for TEVA PHARMACEUTICALS, INC may improve if Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities. (PubMed) delivers favorable follow-through.
- Portfolio and strategy teams should assess the potential market entry of this generic product and its implications for pricing and competition.
What Would Change This Assessment
- This becomes more urgent if Monitor the FDA's review timeline and any subsequent approval announcements for ANDA219413.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA TA — ANDA219413
FDAhigh relevance
Entity match (teva pharmaceuticals inc); Regulatory pathway relevance (nda)
FDA document
View sourceClass 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceBsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View sourceRetrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceToxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceImmunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceACP-204 in Adults With Alzheimer's Disease Psychosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTrial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Gut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceNanomaterial-based vaccines: An advanced approach against rotavirus: A review article.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceImmunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceNanotechnology-mediated podocyte injury repair: mechanistic exploration and therapeutic prospects.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceLysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Related Signals
- TEVA Pharmaceuticals submits ANDA219413 for FDA review
Regulatory Approval
Related Regulatory Precedents
FDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
Over the years, FDA has worked to increase communication between Agency staff and applicants during the review of novel drug and original biologic applications. The goal has been to enhance the transparency, predictability, effectiveness, and efficiency of the review process.
SourceFDA
S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
SourceFDA
FDA-TRACK: Prescription Drug User Fee Act Review Goals Summary
SourceFDA
FDA TA — ANDA219413
Application ANDA219413. Sponsor: TEVA PHARMACEUTICALS, INC.. Submission status: TA. Submission type: ORIG. Review priority: STANDARD.
Source